Kirkland & Ellis and Arnold & Porter Kaye Scholer LLP have advised Curium. Covington & Burling LLP and Ropes & Gray LLP have advised Lantheus. Curium...
Curium to Acquire Lantheus in $8 Billion Merger
Oberland Capital’s $600 Million Investment in Biohaven
Covington & Burling advised Biohaven Ltd. on the transaction, and Cooley advised Oberland Capital. Biohaven Ltd. (NYSE: BHVN) announced it has entered into an agreement with...
Seres Therapeutics’ VOWST Asset Purchase Agreement With Nestlé Health Science
Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
AbbVie’s Acquisition of Cerevel Therapeutics
Kirkland & Ellis advised AbbVie, Latham & Watkins advised Cerevel Therapeutics, Skadden advised Centerview partners LLC, as financial advisor to Cerevel Therapeutics in the transaction. AbbVie...
Otsuka’s Collaboration with ShapeTX
Latham & Watkins advised ShapeTX on the deal. Otsuka Pharmaceutical Co., Ltd. and ShapeTX announced a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
Ascendis Pharma’s $150 Million Royalty Funding Agreement with Royalty Pharma
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Sonoma Biotherapeutics’ Collaboration Agreement with Regeneron Pharmaceuticals
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
Anima Biotech’s Collaboration with AbbVie
Latham & Watkins advised Anima in the transaction. AbbVie (NYSE: ABBV) and Anima Biotech (Anima) have announced a collaboration to discover and develop mRNA biology modulators...
Bionano Genomics’ Acquisition of Purigen Biosystems
Latham & Watkins LLP represented Purigen in the transaction. Bionano Genomics, Inc. (NASDAQ: BNGO) has entered into a definitive agreement to acquire Purigen Biosystems, Inc., a...
Directional Aviation’s Financial Investment in Alder Fuels
Latham & Watkins LLP represented Adler Fuels in the transaction. Directional Aviation has announced that it is making a financial investment in Alder Fuels, a clean tech...